CBD dampens activity in brain regions associated with psychosis, study shows
August 30, 2018Research and Development CBD, King's College London, Kings College London, Marijuana, psychosis, study
Cannabidiol (CBD), one of the major constituents of cannabis, may be beneficial for patients with psychotic disorders due to its …
AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes
August 30, 2018Research and Development, Sales and Marketing AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes
AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for …
Opioid prescriptions hit 15 year low, as FDA’s Gottlieb reaffirms commitment against crisis
August 30, 2018Medical Communications FDA, opioid crisis, prescriptions, scott gottleib
The amount of opioids prescribed to patients in the United States has fallen to a 15 year low according to …
Jazz Pharma’s acute myeloid leukaemia drug scores EU approval
August 29, 2018Research and Development, Sales and Marketing Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, leukaemia, pharma
Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …
Emergent snaps up Adapt and its opioid overdose therapy for $735m
August 29, 2018Research and Development, Sales and Marketing Emergent, Narcan, naloxone, opioid crisis, opioids, pharma
Emergent BioSolutions has announced it has signed an agreement to acquire Adapt Pharma at a valuation of $735 million, a …
NHS guidance suggests mental health therapists should be brought into GP surgeries
August 29, 2018Research and Development England, GP, NHS, guidance, psychology, psychotherapy
New NHS guidelines will encourage doctors to incorporate mental health therapists into practice surgeries in an effort to bring more …
FDA warns against King Bio products after company expands recall
August 29, 2018Research and Development Contamination, FDA, homeopathy, king bio, recall
The US Food and Drug Administration is warning consumers and pet owners not to use products that have been manufactured …
Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up
August 29, 2018Research and Development CAR T, CAR-T, Jobs, Kymriah, Novartis
Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …
Eisai’s weight loss drug lorcaserin found safe in major study
August 28, 2018Manufacturing and Production, Research and Development, Sales and Marketing Eisai, lorcaserin, safety, study, weight loss
Eisai’s weight loss drug lorcaserin does not increase people’s risk of major cardiovascular events according to a study of 12,000 …
Ionis/Akcea’s ultra-rare disease drug rejected by FDA
August 28, 2018Manufacturing and Production, Sales and Marketing Akcea, FDA, Ionis, familial chylomicronemia syndrome, pharma, rare disease
The FDA has opted to refuse approval to Akcea and Ionis’ Waylivra (volanesorsen) for the treatment of the ultra-rare hereditary …
Researchers develop anti-nicotine addiction drugs
August 28, 2018Manufacturing and Production, Research and Development, Sales and Marketing addiction, candidates, drug, nicotine, research, washington state university
Washington State University researchers have developed an array of drug candidates which they believe may help tackle addiction to nicotine. …
Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies
August 28, 2018Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma
Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …
Russian trolls spread vaccine misinformation on Twitter
August 28, 2018Manufacturing and Production, Medical Communications, Sales and Marketing Russia, misinformation, public health, study, vaccines
Twitter bots and Russian trolls post content about vaccination at significantly higher rates than normal users, a new study has …
Dompé gives the FDA its first approved neurotrophic keratitis treatment
August 24, 2018Medical Communications, Sales and Marketing Dompe, FDA, Oxervate, eye disease, pharma
Milan-based biotech firm Dompé has revealed that the FDA has awarded approval in the US to its Oxervate (cenegermin-bkbj ophthalmic …
Top Ten most popular articles on Pharmafile.com this week
August 24, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing India, Ireland, manufacturin, san francisco, top 10
As summer comes to an end manufacturing dominated the news, with jobs lost in both Ireland and San Francisco. Meanwhile …
Homeopathic medicines specialist King Bio enacts nationwide recall
August 24, 2018Medical Communications asheville, homeopathy, king bio, nc, recall
The Asheville-based drug maker King Bio is recalling 32 children’s medicines because of potential ‘microbial contamination’. The homeopathic medicines specialist …
Generics could save US Medicare $1 billion per year
August 24, 2018Medical Communications Medicare, United States, branded, generics, marketing, savings
The United States national health insurance programme Medicare could have save $1 billion through the use of generic drugs according …
Government publishes no-deal Brexit guidance, health secretary tells pharma companies to stockpile medicines
August 24, 2018Medical Communications ABPI, EU, UK, brexit, government, stockpiling
The British Government has published a document offering guidance as to what should be expected in the case of a …
GE Healthcare set to open biotech hub in Uppsala, Sweden
August 23, 2018Manufacturing and Production, Research and Development GE Healthcare, Sweden, Testa Centre, Uppsala, biotech
The American multinational GE Healthcare is opening a 27,000-sq-ft innovation centre in Uppsala, Sweden in an effort to boost the …
AstraZeneca shocked as inhaler fails to outclass GSK rival in COPD
August 23, 2018Research and Development AstraZeneca, COPD, GSK, anoro, inhaler, pharma
Researchers at AstraZeneca have been left scratching their heads as new Phase 3b results for its inhaler, Bevespi Aerosphere, posted …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
